Jr, Schneck, M
Blood Sugar Regulation: As a GLP-1 receptor agonist, Ozempic stimulates insulin release following meals while inhibiting glucagon to decrease blood glucose levels
Just a few weeks after the full results of SURMOUNT-5 crowned Eli Lillys GLP-1/GIP tirzepatide king of the GLP-1s, Regeneron announced it will pay Hansoh Pharma $80M upfront and up to $1.93B in milestone payments for its Phase 3-stage GLP-1/GIP drug, HS-20094
Licensing concerns, sterility issues, and increased regulatory oversight are all in play, meaning that for those seeking alternatives to FDA-approved versions of Zepbound, Mounjaro, Ozempic, and Wegovy, the window for compounding access may be narrowing
Since tirzepatide has a half-life of approximately 5 days and its effects on gastric emptying persist throughout the dosing interval, the specific day matters less than maintaining consistent timing and monitoring your labs regularly